Workflow
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
Globenewswireยท2025-08-01 11:30

Group 1 - Aptose Biosciences Inc. will hold a reconvened shareholder meeting on August 22, 2025, to vote on the appointment of Ernst & Young LLP as the new independent auditor [1][2] - The selection of Ernst & Young was based on their expertise, capabilities, and understanding of the company's industry [2] - The original meeting held on May 27, 2025, was adjourned to complete the search for a successor independent auditor [1] Group 2 - Only registered shareholders and duly appointed proxyholders as of April 22, 2025, will be entitled to vote and ask questions at the reconvened meeting [3] - Proxies from the original meeting will remain effective unless properly revoked, and new forms of proxies are not being distributed [4] - Registered shareholders who have not previously deposited a form of proxy may do so no later than 48 hours before the reconvened meeting [4] Group 3 - Aptose is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [5] - The company's lead product, tuspetinib (TUS), is being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) [5]